Intubation within
72h of birth, n (%)
|
30(40%)
|
30(40%)
|
1.0 (0.68 to 1.48)
|
>0.99***
|
Secondary outcomes
(Major complications)
n (%) CT
|
|
|
|
|
IVH
|
07
|
09
|
0.9418
(0.49 – 1.50)
|
>0.99***
|
BPD
|
06
|
09
|
0.85
(0.41 – 1.43)
|
0.79***
|
hsPDA
|
28
|
30
|
1.07
(0.75 – 1.47)
|
0.74***
|
NEC
|
03
|
04
|
0.92
(0.33 – 1.68)
|
>0.99***
|
Pneumothorax
|
01
|
02
|
0.50
(0.04 – 5.40)
|
0.99***
|
LOS
|
27
|
30
|
1.038
(0.72 – 1.43)
|
0.87***
|
ROP
|
08
|
10
|
0.96
(0.51 – 1.49)
|
>0.99***
|
Median (IQR) duration of MV (days)
|
6.5
(5.5-7)
|
6.25
(5.5-7)
|
–
|
0.40#
|
Median (IQR) duration of non-invasive respiratory
support (days)
|
6 (5-6)
|
6(5.25-6.5)
|
–
|
0.50#
|
Median (IQR) Duration of Supplemental Oxygen |
5(3-11) |
5(3-14) |
– |
0.90# |
Repeat dose of surfactant,
n (%)
|
13 (17.33%)
|
11 (14.66%)
|
–
|
0.82**
|
Adverse events during surfactant administration |
|
|
|
|
Transient desaturation/ bradycardia), n (%) |
9 (12%) |
11 (14.66%) |
– |
0.63** |
Regurgitation, n (%) |
4 (5.33%) |
3 (4%) |
– |
0.69** |
Median (IQR)
length of hospital stay (days)
|
30.5(22-39)
|
26 (18.5-41)
|
–
|
0.56#
|
Survival n (%)
|
54 (72%)
|
52 (69.33%)
|
1.07
(0.76 -1.57)
|
0.86***
|